NVUS News and Press, Novus Therapeutics Inc. From 04/30/19

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that it has entered into definitive agreements with several institutional and accredited investors for th...

Thinly traded nano cap Novus Therapeutics ( NVUS -28.1% ) slumps on more than a 5x surge in volume, albeit on turnover of only 145K shares, in response to results from two Phase 1 studies evaluating lead candidate OP0201. More news on: Novus Therapeutics, Inc., Healthcare stocks news, ...

OP0201 Was Safe and Well-Tolerated in Healthy Adults and Adults with Acute Otitis Media Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced results ...

Novus Therapeutics (NASDAQ: NVUS ): Q4 GAAP EPS of -$0.49  misses by $0.09 . Cash and cash equivalents of $12.97M Press Release More news on: Novus Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, ,

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced financial results for the quarter and year ended December 31, 2018 and provided updates on the OP0201 dev...

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that the company will participate at the 8th Annual SVB Leerink Healthcare Conference on Thursday, Februa...

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that it has dosed the first patients in a phase 2a trial of OP0201, the company’s lead product can...

Novus Therapeutics, Inc. (“Novus”) is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (“ENT”). Novus has two technologies, each that has the potential to be developed for multiple ENT indic...

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that it has dosed the first adult subjects in study C-001, a phase 1 pharmacodynamics clinical trial of O...

Gainers: Maxwell Technologies (NASDAQ: MXWL ) +50% . Therapix Biosciences (NASDAQ: TRPX ) +24% . Continental Materials (NYSEMKT: CUO ) +24% . PHI (NASDAQ: PHII ) +22% . Orgenesis (NASDAQ: ORGS ) +19% . The Ultimate Software Group (NASDAQ: ULTI ) +20% . Aileron Therapeutics (NASDAQ: ...